Progress on economic burden of patients with drug-resistant tuberculosis

doi:10.19982/j.issn.1000-6621.20230018

Abstract

Abstract:

While the global tuberculosis epidemic has shown a decline trend in recent years, the economic burden induced by drug-resistant tuberculosis has increased. The reason is that the treatment of drug-resistant tuberculosis is expensive, the course of the disease is prolonged, and the side effects of treatment are serious. The authors reviewed the economic burden of drug-resistant tuberculosis and revealed the current research status of the economic burden of drug-resistant tuberculosis and its influencing factors to provide a reference for subsequent researches and medical insurance policy formulation.

Key words: Tuberculosis, Drug resistance, Economics, medical, Cost of illness, Review literature as topic

CLC Number:

R521

Wang Boning, Li Tao, Chen Wei. Progress on economic burden of patients with drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2023, 45(6): 607-612. doi: 10.19982/j.issn.1000-6621.20230018

References 40

[1]	王仲元. 耐药结核病的研究进展. 传染病信息, 2018, 31(1):19-23. doi:10.3969/j.issn.1007-8134.2018.01.005. doi: 10.3969/j.issn.1007-8134.2018.01.005
[2]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[3]	Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J, 2014, 43(6):1763-1775. doi:10.1183/09031936.00193413. doi: 10.1183/09031936.00193413 pmid: 24525439
[4]	陈文. 卫生经济学. 4版. 北京: 人民卫生出版社, 2017.
[5]	Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol, 2014, 20(4):327-337. doi:10.3350/cmh.2014.20.4.327. doi: 10.3350/cmh.2014.20.4.327 pmid: 25548737
[6]	何敏媚, 何闽江, 崔斌. 疾病经济负担研究进展. 中国老年学杂志, 2010, 30(18):2700-2702. doi:10.3969/j.issn.1005-9202.2010.18.071. doi: 10.3969/j.issn.1005-9202.2010.18.071
[7]	Sun X, Jackson S, Carmichael G, et al. Catastrophic medical payment and financial protection in rural China: evidence from the New Cooperative Medical Scheme in Shandong Province. Health Economics, 2009, 18(1): 103-119. doi:10.1002/hec.1346. doi: 10.1002/hec.1346 pmid: 18283715
[8]	Mullerpattan JB, Udwadia ZZ, Banka RA, et al. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India. Indian J Tuberc, 2019, 66(1):87-91. doi:10.1016/j.ijtb.2018.04.011. doi: 10.1016/j.ijtb.2018.04.011 URL
[9]	Wingfield T. World Health Organisation Tuberculosis Patient Costs Surveys: a handbook. Geneva: World Health Organization, 2017.
[10]	杨天池, 陈琴, 陈同, 等. 宁波市利福平耐药肺结核患者家庭灾难性医疗支出及其影响因素分析. 中国防痨杂志, 2019, 41(11):1191-1196. doi:10.3969/j.issn.1000-6621.2019.11.009. doi: 10.3969/j.issn.1000-6621.2019.11.009
[11]	朱磷扬, 杨皓舒, 仲崇桥, 等. 连云港市耐利福平结核病人主要危险因素及经济负担. 江苏预防医学, 2016, 27(3):268-270. doi:10.13668/j.issn.1006-9070.2016.03.04. doi: 10.13668/j.issn.1006-9070.2016.03.04
[12]	王倩, 张修磊, 阴佳. 山东省耐多药肺结核患者医疗费用灾难性支出分析研究. 河南预防医学杂志, 2020, 31(12):918-920. doi:10.13515/j.cnki.hnjpm.1006-8414.2020.12.013. doi: 10.13515/j.cnki.hnjpm.1006-8414.2020.12.013
[13]	张广川. 广州市耐多药肺结核经济负担及影响因素分析. 广州:广东药科大学, 2021.
[14]	Nam VX, Nhung NV, Hoa NB, et al. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions. Int J Tuberc Lung Dis, 2018, 22(8):912-917. doi:10.5588/ijtld.18.0039. doi: 10.5588/ijtld.18.0039 pmid: 29991401
[15]	Florentino JL, Arao RML, Garfin AMC, et al. Expansion of social protection is necessary towards zero catastrophic costs due to TB: The first national TB patient cost survey in the Philippines. PLoS One, 2022, 17(2):e264689. doi:10.1371/journal.pone.0264689. doi: 10.1371/journal.pone.0264689
[16]	Lee S, Kim MJ, Lee SH, et al. Comparison of Disability-Adjusted Life Years (DALYs) and Economic Burden on People With Drug-Susceptible Tuberculosis and Multidrug-Resistant Tuberculosis in Korea. Front Public Health, 2022, 10:848370. doi:10.3389/fpubh.2022.848370. doi: 10.3389/fpubh.2022.848370
[17]	Fitzpatrick C, Floyd K. A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. Pharmacoeconomics, 2012, 30(1):63-80. doi:10.2165/11595340-000000000-00000. doi: 10.2165/11595340-000000000-00000 pmid: 22070215
[18]	Rouzier VA, Oxlade O, Verduga R, et al. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador. Int J Tuberc Lung Dis, 2010, 14(10):1316-1322. pmid: 20843424
[19]	van den Hof S, Collins D, Hafidz F, et al. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis, 2016, 16(1):470. doi:10.1186/s12879-016-1802-x. doi: 10.1186/s12879-016-1802-x
[20]	Mullerpattan JB, Udwadia ZZ, Banka RA, et al. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India. Indian J Tuberc, 2019, 66(1):87-91. doi:10.1016/j.ijtb.2018.04.011. doi: 10.1016/j.ijtb.2018.04.011 URL
[21]	Pedrazzoli D, Siroka A, Boccia D, et al. How affordable is TB care? Findings from a nationwideTB patient cost survey in Ghana. Trop Med Int Health, 2018, 23(8):870-878. doi:10.1111/tmi.13085. doi: 10.1111/tmi.13085 pmid: 29851223
[22]	Nhung NV, Hoa NB, Anh NT, et al. Measuring catastrophic costs due to tuberculosis in Viet Nam. Int J Tuberc Lung Dis, 2018, 22(9):983-990. doi:10.5588/ijtld.17.0859. doi: 10.5588/ijtld.17.0859 pmid: 30092862
[23]	Timire C, Ngwenya M, Chirenda J, et al. Catastrophic costs among tuberculosis-affected households in Zimbabwe: A national health facility-based survey. Trop Med Int Health, 2021, 26(10):1248-1255. doi:10.1111/tmi.13647. doi: 10.1111/tmi.13647 URL
[24]	Berhanu RH, Schnippel K, Kularatne R, et al. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?. Int J Tuberc Lung Dis, 2019, 23(3):358-362. doi:10.5588/ijtld.17.0837. doi: 10.5588/ijtld.16.0837 pmid: 30940300
[25]	Gomez MA, Millet JP, Maldonado J, et al. The costs of MDR/XDR tuberculosis in Barcelona (Spain): Cases treated with DOTs/DOT plus in a specialized centre. Eur Respir J, 2016,48. doi:10.1183/13993003.congress-2016.PA2718. doi: 10.1183/13993003.congress-2016.PA2718
[26]	Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J, 2014, 43(2):554-565. doi:10.1183/09031936.00079413. doi: 10.1183/09031936.00079413 pmid: 23949960
[27]	Feuth T, Patovirta R, Grierson S, et al. Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. Int J Tuberc Lung Dis, 2021, 25(7):554-559. doi:10.5588/ijtld.20.0892. doi: 10.5588/ijtld.20.0892 pmid: 34183100
[28]	Lee S, Kim MJ, Lee SH, et al. Comparison of Disability-Adjusted Life Years (DALYs) and Economic Burden on People With Drug-Susceptible Tuberculosis and Multidrug-Resistant Tuberculosis in Korea. Front Public Health, 2022, 10:848370. doi:10.3389/fpubh.2022.848370. doi: 10.3389/fpubh.2022.848370
[29]	陈丽金, 周颖, 钟云, 等. 广东省耐多药结核病患者疾病经济负担研究. 中国卫生经济, 2021, 40(3):72-75.
[30]	张加胜. 耐多药肺结核患者的医疗费用、经济负担及补偿现状——38例患者个案研究. 济南:山东大学, 2011.
[31]	热孜亚木. 2013—2017年新疆某专科医院耐药肺结核患者医疗费用变化情况及影响因素研究. 乌鲁木齐:新疆医科大学, 2018.
[32]	闫赟. 中国5城市耐多药肺结核患者诊治及管理现状研究. 济南:山东大学, 2010.
[33]	Muttamba W, Tumwebaze R, Mugenyi L, et al. Households experiencing catastrophic costs due to tuberculosis in Uganda: magnitude and cost drivers. BMC Public Health, 2020, 20(1):1409. doi:10.1186/s12889-020-09524-5. doi: 10.1186/s12889-020-09524-5 pmid: 32938411
[34]	Kilale AM, Pantoja A, Jani B, et al. Economic burden of tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected households. BMC Public Health, 2022, 22(1):600. doi:10.1186/s12889-022-12987-3. doi: 10.1186/s12889-022-12987-3 pmid: 35351063
[35]	Grobler L, Nagpal S, Sudarsanam TD, et al. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev, 2016, 2016(6): CD006086. doi:10.1002/14651858.CD006086.pub4. doi: 10.1002/14651858.CD006086.pub4
[36]	Wang Y, McNeil EB, Huang Z, et al. Household financial burden among multidrug-resistant tuberculosis patients in Guizhou province, China. Medicine (Baltimore), 2020, 99(28):e21023. doi:10.1097/MD.0000000000021023. doi: 10.1097/MD.0000000000021023
[37]	申丽君, 王艺曈, 李雪, 等. 基于疗程费用测算耐药结核病患者药物负担. 中国防痨杂志, 2019, 41(9):962-967. doi:10.3969/j.issn.1000-6621.2019.09.010. doi: 10.3969/j.issn.1000-6621.2019.09.010
[38]	叶家利, 吴惠忠, 邹霞, 等. 162例耐多药结核病患者经济负担影响因素分析. 热带医学杂志, 2020, 20(4):441-445. doi:10.3969/j.issn.1672-3619.2020.04.005. doi: 10.3969/j.issn.1672-3619.2020.04.005
[39]	孙强, 闫赟, 边学峰, 等. 耐多药肺结核患者医疗费用及经济负担分析. 中国卫生经济, 2011, 30(1):33-35. doi:10.3969/j.issn.1003-0743.2011.01.012. doi: 10.3969/j.issn.1003-0743.2011.01.012
[40]	Wang Y, Chen H, Huang Z, et al. Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study. Patient Prefer Adherence, 2019, 13:1641-1653. doi:10.2147/PPA.S219920. doi: 10.2147/PPA.S219920 URL